MTCH2

Across TCGA pan-cancer cohorts, MTCH2 mass-spec protein differs between tumor and matched normal tissue in 7 of 18 cancer types tested, making tumor–normal expression one of MTCH2’s most consistent transcriptional readouts.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where MTCH2 mass-spec protein is repressed in tumor relative to normal tissue. In most cancer types MTCH2 is over-expressed in tumor, although a few such as CCRCC and HNSC show the opposite, repressed pattern.

CCRCC, LUAD, and COAD are the cancer types where MTCH2 tumor–normal differential expression is most reproducible.

mass-spec protein tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in MTCH2 mass-spec protein (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
CCRCC	Female	II,III,IV	−1.244	<.001	12	view →
LUAD	Female	II,III,IV	+0.783	<.001	9	view →
COAD	All	III,IV	+0.245	<.001	9	view →
LSCC	Male	All	+0.498	<.001	8	view →
PDAC	All	IV	+0.677	.027	2	view →
OV	All	All	+0.373	.007	2	view →
HNSC	All	II,III,IV	−0.150	.040	2	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 7 strongest of 7 lineages.

MTCH2–CCRCC

Open the CCRCC breakdown →